Last reviewed · How we verify
NCT04869267: ACT
Acceptance and Commitment Therapy in Patients With Advanced Lung Cancer
NA trial testing Acceptance and Commitment Therapy (ACT) in Lung Cancer in 160 participants. Completed in 7 January 2022.
7 January 2022
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 160 |
| Start date | 1 July 2021 |
| Primary completion | 7 January 2022 |
| Estimated completion | 7 January 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Acceptance and Commitment Therapy (ACT)
- Usual care
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Advanced Cancer — all drugs for Advanced Cancer →
Sponsor
Chinese University of Hong Kong
Who can join
18 and older, any sex, with Lung Cancer or Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lung cancer is a malignant tumor that has transformed from a single cancer disease into one of the most striking global health problems. Lung cancer has an insidious onset, and most patients are first diagnosed with the middle and advanced stage. Cancer related fatigue is the most common and distressing symptom reported by lung cancer patients. For cancer patients, fatigue has lasting impact on physical, psychological and social functions, interferes with activities and participating in life events, thereby worsening the health-related quality of life. Acceptance and Commitment Therapy (ACT) is the third-wave cognitive behavioral therapy to improve functioning and health-related quality of life by increasing psychological flexibility. The study aims to examine the effectiveness of ACT on fatigue interference and health-related quality of life in patients with advanced lung cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effects of Acceptance and Commitment Therapy on fatigue interference and health-related quality of life among patients with advanced lung cancer: A pilot randomized controlled trial.
Li H, Jin X, Ng MSN, Mann KF, et al · · 2022 · cited 20× · PMID 36092683 · DOI 10.1016/j.apjon.2022.100102 -
Application of acceptance and commitment therapy in cancer-related fatigue management: insights from clinical trials and future perspectives.
Chen X, Li Z. · · 2025 · cited 1× · PMID 39964319 · DOI 10.1097/js9.0000000000002305
Verify or expand the search:
- PubMed search for NCT04869267
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acceptance and Commitment Therapy (ACT)
Trials testing the same drug.
- NCT06704061 — Online Yoga vs Acceptance and Commitment Therapy for Treating Chronic Musculoskeletal Pain · NA · recruiting
- NCT07066488 — Brief ACT Intervention for Problem Gambling: A Pilot Study · NA · not yet recruiting
- NCT07175402 — Feasibility and Acceptability of an Online ACT Intervention for Disorders of Gut-Brain Interaction - Beta Trial · NA · completed
- NCT06887751 — Feasibility and Acceptability of an Online ACT Intervention for Disorders of Gut-Brain Interaction · NA · completed
- NCT07256093 — The Effectiveness of Acceptance and Commitment Therapy (ACT) on Dysfunctional Attitudes and Difficulties in Emotion Regu · NA · completed
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04869267 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 4 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04869267.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing